ANEB — Anebulo Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $47.25m
- $32.25m
- 34
- 20
- 28
- 16
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.16 | ||
| Price to Tang. Book | 3.16 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -53.5% | ||
| Return on Equity | -71.49% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company. It is engaged in developing treatments for cannabis toxicity, such as unintentional cannabis poisoning, acute cannabinoid intoxication (ACI) and the landscape of acute cannabis-induced conditions. Its lead product candidate is selonabant, a potent, small molecule antagonist of cannabinoid binding receptor type-1 (CB1), the primary receptor involved in the psychotropic effects of cannabinoids, with the potential to address the unmet medical need for a therapy to treat cannabis toxicity. Selonabant is orally bioavailable, rapidly absorbed, and has also been formulated for intravenous administration. Selonabant is intended to rapidly reverse the negative effects of cannabis-induced toxicity and reduce time to recovery. It is also prioritizing the advancement of a selonabant intravenous (IV) formulation as a potential treatment for pediatric patients with cannabis-induced CNS depression.
Directors
- Last Annual
- June 30th, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- April 23rd, 2020
- Public Since
- May 7th, 2021
- No. of Shareholders
- 13
- No. of Employees
- 2
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 41,084,731
- Address
- Jfl Capital Management, LAKEWAY, 78734
- Web
- https://www.anebulo.com/
- Phone
- +1 5125980931
- Auditors
- EisnerAmper LLP
Upcoming Events for ANEB
Q4 2025 Anebulo Pharmaceuticals Inc Earnings Release
Similar to ANEB
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the Anebulo Pharmaceuticals share price?
As of Today at 19:15 UTC, shares in Anebulo Pharmaceuticals are trading at $1.15. This share price information is delayed by 15 minutes.
How has the Anebulo Pharmaceuticals share price performed this year?
Shares in Anebulo Pharmaceuticals last closed at $1.15 and the price had moved by -63.14% over the past 365 days. In terms of relative price strength the Anebulo Pharmaceuticals share price has underperformed the S&P500 Index by -66.76% over the past year.
What are the analyst and broker recommendations for Anebulo Pharmaceuticals?
The overall consensus recommendation for Anebulo Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Anebulo Pharmaceuticals dividend yield?
Anebulo Pharmaceuticals does not currently pay a dividend.
Does Anebulo Pharmaceuticals pay a dividend?
Anebulo Pharmaceuticals does not currently pay a dividend.
When does Anebulo Pharmaceuticals next pay dividends?
Anebulo Pharmaceuticals does not currently pay a dividend.
How do I buy Anebulo Pharmaceuticals shares?
To buy shares in Anebulo Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Anebulo Pharmaceuticals?
As of the previous close price of $1.15, shares in Anebulo Pharmaceuticals had a market capitalisation of $47.25m.
Where are Anebulo Pharmaceuticals shares listed?
Here are the trading details for Anebulo Pharmaceuticals:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: ANEB
What kind of share is Anebulo Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Anebulo Pharmaceuticals is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Anebulo Pharmaceuticals share price forecast for 2025?
The analyst consensus target price for shares in Anebulo Pharmaceuticals is $8.00. That is 595.65% above the last closing price of $1.15.
Analysts covering Anebulo Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$0.26 for the next financial year.
Find out moreWhat is the trend in the Anebulo Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Anebulo Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -37.21%.
As of the last closing price of $1.15, shares in Anebulo Pharmaceuticals were trading -30.14% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Anebulo Pharmaceuticals PE Ratio?
The Anebulo Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.15.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Anebulo Pharmaceuticals?
We do not have data on Anebulo Pharmaceuticals' directors